Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 1997

View Archived Issues

Annual Report: CellPro

Annual Report: Cangene

ZymoGenetics/Novo Nordisk isolate anticlotting agent

EPO activators/agonists described by J&J and Affymax

X-ray contrast agents from Schering AG

Human Genome Sciences describes MCP-4 polypeptide

Anti-factor Xa compounds disclosed by RPR

Zeneca describes ET antagonists

Retinoid series for cancer

BASF prepares dolastatin derivatives

TK inhibitors disclosed by RCT

HMR synthesizes potent AChE inhibitor

Combination Remune/triple anti-HIV therapy trial begins

Neuraminidase inhibitor holds promise for flu

Approval anticipated for TMR using Heart Laser

Biopharmaceutics/ABS form advisory team to advance filings for anticancer drug

Alza/Alkermes stock purchase and development agreements

Clinical development of HIV immunotherapeutic advances

Gliatech's ADCON-L nears FDA approval

Nymox drug candidate for AD to enter phase I

Inex and Schering-Plough complete research collaboration

Positive phase I safety profile for Immunex's new product candidate

Dermik launches new acne medication

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...